‘Golden Visa’ Investment in Portugal rises 41.9% in 2022

 

Investment raised through ‘golden visas’ in Portugal last year rose to EUR 654.2 million, an increase of 41.9 percent compared to the previous year.

According to data from the Foreigners and Borders Service (SEF), in 2022, 1,281 Residence Permits for Investment (ARI), also known as golden visas, were granted.

A total of 94 golden visas were granted in January, 94 in February, 73 in March, 121 in April, 112 in May, 155 in June, 80 in July, 77 in August, 120 in September, 83 in October, 121 in November and 151 in December, the same source added.

Real estate investment in Portugal increases by 39% in 2022 to EUR 3 billion

Last year, 1,533 residence permits were granted to reunited family members, 192 of which were in December.

Since the creation of the golden visa, which was implemented with the aim of attracting foreign investment, whose continuity is being evaluated, 11,535 residence permits have already been granted: two in 2012, 494 in 2013, 1,526 in 2014, 766 in 2015, 1,414 in 2016, 1,351 in 2017, 1,409 in 2018, 1,245 in 2019, 1,182 in 2020, 865 in 2021 and 1,281 in 2022.

In terms of the acquisition of real estate, visas granted so far total 10,593 and an investment of EUR 6,041 million, of which €534.1 million corresponds to the purchase of real estate for urban rehabilitation (1,485 ARI).

‘Golden visa’ investment jumps nearly 40% in Portugal

With regard to the capital transfer criterion, 920 capital transfers have been granted to date, amounting to EUR 712 million. The criterion for creating jobs totals the attribution of 22 golden visas.

By nationalities, China leads (5,247), followed by Brazil (1,168), Turkey (546), the United States (537), and South Africa (507).

Since the beginning of the program, 18,808 residence permits have been granted to reunited family members.

Other articles

China

Ho family´s Estoril-Sol ensures concession of casinos in Portugal for 15 years

China

Portuguese pharma company to launch “very promising” Parkinson treatment based on University of Macau research